A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease
2022-06-27
عنوان الدراسة
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease
داعم الدراسة
Celgene
دواء الدراسة
Ozanimod HCl
رقم بروتوكول الدراسة
RPC01-3204
حالة الدراسة
Ongoing
موقع الدراسة
KAUH-J
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.